Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVV-01 Combined With AK112 in Advanced Soft Tissue Sarcoma
NCT07650838Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label, single-arm trial of OVV-01 in soft tissue sarcoma (STS), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate up to 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
OVV-01
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07650838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650838.